Researchers from the Walter and Eliza Hall Institute have solved a mystery about how a promising new class of anticancer drugs works. [ + ]

The funding partners of the Grand Challenges family of grant programs, led by the Bill & Melinda Gates Foundation, are inviting innovators to apply for three upcoming opportunities. [ + ]

Paradigm Biopharmaceuticals seeks to investigate if the drug ZILOSUL can resolve bone bruising arising from sporting or accidental injuries to the knee such as a ruptured anterior cruciate ligament (ACL). [ + ]

The Alan Alda Center for Communicating Science, based in the US, has welcomed the Australian National University as its first international affiliate. [ + ]

Prostate Cancer Foundation Australia (PCFA) and the Movember Foundation are funding two new clinical trials that will potentially revolutionise the way prostate cancers are monitored and treated. [ + ]

electroCore is running two new trials of its gammaCore non-invasive vagus nerve stimulation (nVNS) therapy in episodic migraine. [ + ]

The Australian Academy of Science's National Committee for Chemistry has developed a strategic vision for Australian chemistry for the next decade. [ + ]

The Grattan Institute has released a report calling for the government to change the way it pays for pathology testing, in a move which would save up to $175 million a year. [ + ]

Prescient Therapeutics has marked two key milestones — the dosing of the last patient in the escalation stage of its Phase Ib breast cancer trial and the appointment of a new CEO. [ + ]

Regenerative medicine company Avita Medical has appointed MSM Medical as its newest European distributor and sold its respiratory business to Medical Developments International. [ + ]

Stem cell company Cynata Therapeutics has received an R&D Tax Incentive refund of $932,580.65 for the 2014–15 financial year. [ + ]

Sophia Genetics and Integrated DNA Technologies are helping hospitals address their need to adopt next-generation sequencing (NGS) tests for routine clinical diagnostics. [ + ]

An American-Australian research team has identified what may be the initial target of the immune response that causes type 1 diabetes. [ + ]

Particle & Surface Sciences has been appointed the exclusive distributor for Surface Measurement Systems in Australia and New Zealand. [ + ]

Australian and British scientists are collaborating on the creation of a single miniature biodegradable device that can not only track a disease, but can also treat it. [ + ]